Thomas Hach

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

Giulia Ferrannini, Thomas Hach, Susanne Crowe et al. · Diabetes Care · 2015 · 357 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin

Ele Ferrannini, Andreas Berk, Stefan Hantel et al. · Diabetes Care · 2013 · 220 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska et al. · Diabetes Obesity and Metabolism · 2013 · 210 citations

Medicine, Pharmacology, Pharmacotherapy +17

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Vlado Perkovic, Jonathan Barratt, Brad H. Rovin et al. · New England Journal of Medicine · 2024 · 162 citations

Medicine, Immunology, Nephrology +14

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai et al. · Cardiovascular Diabetology · 2015 · 104 citations · Full text

Medicine, Endocrinology, Pharmacology +15